Language
English
Publication Date
3-1-2024
Journal
Neuropsychopharmacology
DOI
10.1038/s41386-023-01747-5
PMID
37848731
PMCID
PMC10876568
PubMedCentral® Posted Date
10-17-2023
Abstract
GrimAge acceleration has previously predicted age-related morbidities and mortality. In the current study, we sought to examine how GrimAge is associated with genetic predisposition for systemic inflammation and whether psychosocial factors moderate this association. Military veterans from the National Health and Resilience in Veterans study, which surveyed a nationally representative sample of European American male veterans, provided saliva samples for genotyping (N = 1135). We derived polygenic risk scores (PRS) from the UK Biobank as markers of genetic predisposition to inflammation. Results revealed that PRS for three inflammatory PRS markers—HDL (lower), apolipoprotein B (lower), and gamma-glutamyl transferase (higher)—were associated with accelerated GrimAge. Additionally, these PRS interacted with a range of potentially modifiable psychosocial variables, such as exercise and gratitude, previously identified as associated with accelerated GrimAge. Using gene enrichment, we identified anti-inflammatory and antihistamine drugs that perturbate pathways of genes highly represented in the inflammatory PRS, laying the groundwork for future work to evaluate the potential of these drugs in mitigating epigenetic aging.
Keywords
Male, Humans, Genetic Risk Score, Aging, Genetic Predisposition to Disease, Biomarkers, Inflammation, Risk Factors
Published Open-Access
yes
Recommended Citation
Tamman, Amanda J F; Koller, Dora; Nagamatsu, Sheila; et al., "Psychosocial Moderators of Polygenic Risk Scores of Inflammatory Biomarkers in Relation to GrimAge" (2024). Faculty, Staff and Students Publications. 6012.
https://digitalcommons.library.tmc.edu/baylor_docs/6012
Included in
Medical Sciences Commons, Medical Specialties Commons, Mental and Social Health Commons, Psychiatry and Psychology Commons
Comments
This article has been corrected. See Neuropsychopharmacology. 2024 Jan 5;49(4):764.